Aldeyra Therapeutics Faces Class Action Lawsuit Over Drug Trial Issues

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Aldeyra Therapeutics Class Action

Apr. 6, 2026 at 6:45pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image featuring a shattered glass vial or beaker on a clean, monochromatic background, conceptually representing the unreliable drug trial results that led to the class action lawsuit against Aldeyra Therapeutics.The shattered remains of a drug trial symbolize the inconsistent and unreliable results that sparked a class action lawsuit against Aldeyra Therapeutics.San Diego Today

A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. on behalf of investors who purchased the company's securities between November 3, 2023 and March 16, 2026. The lawsuit alleges that Aldeyra failed to disclose inconsistent results from clinical trials of its lead drug candidate reproxalap, which is being investigated as a treatment for dry eye disease.

Why it matters

The lawsuit claims Aldeyra misled investors about the reliability and meaningfulness of its drug trial results, which ultimately led to the FDA issuing a Complete Response Letter rejecting the company's application. This resulted in a significant drop in Aldeyra's stock price, harming investors.

The details

The complaint alleges that during the class period, Aldeyra failed to disclose that the results of the reproxalap clinical trials were inconsistent, and that this inconsistency rendered the positive findings unreliable. On March 17, 2026, Aldeyra announced it had received the Complete Response Letter from the FDA stating there was a lack of substantial evidence that the drug would have the claimed effect, and that the inconsistency of the study results raised serious concerns about the reliability and meaningfulness of the positive findings.

  • The class period is from November 3, 2023 to March 16, 2026.
  • Aldeyra received the Complete Response Letter from the FDA on March 17, 2026.
  • The lead plaintiff deadline for the class action is May 29, 2026.

The players

Aldeyra Therapeutics, Inc.

A biotechnology company focused on developing therapies to treat immune-mediated diseases, including dry eye disease.

Robbins LLP

A law firm representing the plaintiffs in the class action lawsuit against Aldeyra Therapeutics.

Got photos? Submit your photos here. ›

What’s next

The lead plaintiff deadline for the class action lawsuit is May 29, 2026. Shareholders who wish to serve as lead plaintiff must submit their papers to the court by this date.

The takeaway

This case highlights the importance of biotechnology companies being transparent about the reliability and consistency of their drug trial results, as misleading investors can lead to significant legal and financial consequences.